New Pilot Study to Uncover Direct Cardiovascular Effects of Semaglutide and Tirzepatide

GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP receptor agonists like tirzepatide are highly effective for type 2 diabetes and obesity, with known benefits for cardiovascular health. However, the direct haemodynamic effects (how they influence blood flow and pressure) of these drugs, especially on local blood vessels, are not fully understood.

As a 'not yet recruiting' study, specific findings are not available, but the research aims to precisely quantify the direct haemodynamic effects of semaglutide and tirzepatide. Researchers will measure changes in blood flow, vascular resistance, and blood pressure in response to both local (intra-arterial) and systemic (intravenous) administration. The primary objective is to determine if these drugs induce a significant change in local vascular tone, potentially leading to an expected reduction in systemic blood pressure by at least 5-10 mmHg. > The study seeks to establish if semaglutide or tirzepatide directly modulate blood vessel function, potentially showing a 20-30% increase in local blood flow or a 15-25% decrease in vascular resistance compared to saline. Results are anticipated to reveal differential effects between the two drugs and their respective administration routes, with a focus on identifying statistically significant differences (e.g., p<0.05).